Diagnostic Value of GSTP1, RASSF1, AND RASSF2 Methylation in Serum of Prostate Cancer Patients Genetic markers in prostate cancer
Urology Journal,
Vol. 21 No. 03 (2024),
11 May 2024
,
Page 182-188
https://doi.org/10.22037/uj.v20i.8014
Abstract
Purpose: Considering the inadequacy of PSA measurement in the diagnosis of prostate cancer, it is aimed to establish a potential liquid biopsy diagnostic panel.
Materials and Methods: 39 patients who underwent TRUS-biopsy and 15 healthy volunteers were included.
Approximately 15 ml of venous blood samples taken from healthy volunteers and patients before biopsy were
separated as plasma. Hypermethylation status of GSTP1 and RASSF1:RASSF2 genes was revealed in cfDNA
materials collected from plasma samples. Correlation of this epigenetic change detected in PCa, BPH and healthy
volunteer groups with pathology results was examined.
Results: Pathology reports of 39 patients included were 13 PCa, 3 ASAP, 3 HGPIN, and 20 BPH. In total, 3 of the
patients with PCa had positive GSTP1, 4 had RASSF1 and 9 had positive RASSF2 methylation. It was seen that
RASSF2 had the highest sensitivity (69%), specificity (39%) and NPV (80%), while RASSF1 had the highest PPV
(30%). When the binary combinations of genes were examined it was observed that the GSTP1:RASSF1 combination
had the highest sensitivity (46%), specificity (76%) and NPV (82%). When the methylation of all three
genes was examined, it was observed that the sensitivity was quite low (8%), but the specificity (83%) increased
significantly.
Conclusion: Although we observed that the GSTP1 and RASSF1 methylation positivity rates that we examined in
our study were higher in patients without prostate cancer, we found that the RASSF2 methylation rate was higher
in patients with prostate cancer. randomized controlled studies are needed.
- GSTP1
- RASSF1
- RASSF2
- PROSTATE CANCER
How to Cite
References
-Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71:209-249
-Bailey, S.V., ve Brewster, S.F. "Prostate cancer: to screen or not to screen", Archivos Espanoles de Urologia, 64(5): 406-418 (2011).
- Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Med J Aust 1869; 14: 146-147.
- Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2005; 10: 6897-6904.
- Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells - Biology and biomarkers. Nat Rev Clin Oncol 2014; 11: 129-144.
- Yap TA, Lorente D, Omlin A, Olmos D, De Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20: 2553-2558.
- Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P. The origin and mechanism of circulating DNA. Ann N Y Acad Sci 2006; 906: 161-168.
- Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 2015; 61: 112-123.
- Altimari A, Grigioni AD, Benedettini E, Gabusi E, Schiavina R, Martinelli A, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008; 129: 756-762.
- Goessl C, Müller M, Straub B, Miller K. DNA alterations in body fluids as molecular tumor markers for urological malignancies. Eur Urol 2002; 41: 668-676
Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010;2010:17-33.
Goessl C, Krause H, Muller M, Heicappell R, Schrader M, Sachsinger J, et al. Fluorescent methylation-specifi c polymerase chain reaction for DNA-based detection of prostate cancer in bodily fl uids. Cancer Res 2000;60:5941-5.
Amiri, M.; Asadi Samani, L.; Kashi, A. H.; Khadem, N.; Ziaee, S. A. M.; Mowla, S. javad. New Molecular Markers for Prostate Cancer Diagnosis. Urol J 2023, 20, 7687.
Payne SR, Serth J, Schostak M, Kamradt J, Strauss A, Thelen P, et al. DNA methylation biomarkers of prostate cancer:confi rmation of candidates and evidence urine is the most sensitive body fl uid for non-invasive detection. Prostate 2009;69:1257-69.
Roupret M, Hupertan V, Yates DR, Catto JWF, Rehman I, Meuth M, et al. Molecular detection of localized prostate cancer using quantitative methylation-specifi c PCR on urinary cells obtained following prostate massage. Clin Cancer Res 2007;13:1720-5.
Chenwei Li, Zefang Tang, Wenjie Zhang, Zhaochen Ye, Fenglin Liu, GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA, Nucleic Acids Research, Volume 49, Issue W1, 2 July 2021, Pages W242–W246, https://doi.org/10.1093/nar/gkab418
Mandel, P.; Metais, P. Les acides nucléiques du plasma sanguin chez l’homme. C R Seances Soc. Biol. Fil.1948, 142, 241–243
Di Meo, A.; Bartlett, J.; Cheng, Y.; Pasic, M.D.; Yousef, G.M. Liquid biopsy: A step forward towards precision medicine in urologic malignancies. Mol. Cancer 2017, 16, 80.
Elazezy, M.; Joosse, S.A. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol. J. 2018, 16, 370–378.
Schwarzenbach, H.; Hoon, D.S.; Pantel, K. Cell-free nucleic acids as biomarkers in cancer patients.Nat. Rev. Cancer 2011, 11, 426–437.
Sharma, S.; Kelly, T.K.; Jones, P.A. Epigenetics in cancer. Carcinogenesis 2010, 31, 27–36.
Feinberg, A.P.; Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from theirnormal counterparts. Nature 1983, 301, 89–92.
Kulis, M.; Esteller, M. DNA methylation and cancer. Adv. Genet. 2010, 70, 27–56.
Ellinger, J.; Haan, K.; Heukamp, L.C.; Kahl, P.; Buttner, R.; Muller, S.C.; et al. P.J.CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.Prostate 2008, 68, 42–49.
Sunami, E.; Shinozaki, M.; Higano, C.S.; Wollman, R.; Dor_, T.B.; Tucker, S.J.; et al. Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin. Chem. 2009, 55, 559–567.
Constâncio, V.; Nunes, S.P.; Moreira-Barbosa, C.; Freitas, R.; Oliveira, J.; Pousa, I.; et al. Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. Clin. Epigenetics 2019, 11, 175.
Brait, M.; Banerjee, M.; Maldonado, L.; Ooki, A.; Loyo, M.; Guida, E.; et al. Promoter methylation of MCAM, ERalpha and ERbeta in serum ofearly stage prostate cancer patients. Oncotarget 2017, 8, 15431–15440.
Haldrup, C.; Pedersen, A.L.; Ogaard, N.; Strand, S.H.; Hoyer, S.; Borre, M.; et al. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue andliquid biopsies. Mol. Oncol. 2018, 12, 545–560.
Sanchez, B.E.; Aguayo, A.; Martinez, B.; Rodriguez, F.; Marmolejo, M.; Svyryd, Y.; et al. Using Genetic and Epigenetic Markers to Improve Di_erential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients. Clin. Genitourin Cancer 2018, 16, e867–e877.
Reis, I.M.; Ramachandran, K.; Speer, C.; Gordian, E.; Singal, R. Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease. Br. J. Cancer 2015, 113, 460–468.
- Abstract Viewed: 165 times
- 8014/pdf Downloaded: 24 times